| Q40180049 | A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza B Virus Monoclonal Antibody, MHAB5553A, in Healthy Volunteers |
| Q35612523 | A new millennium conundrum: how to use a powerful class of influenza anti-neuraminidase drugs (NAIs) in the community |
| Q56908839 | A primer on strategies for prevention and control of seasonal and pandemic influenza |
| Q34419159 | Adverse cutaneous reactions to influenza vaccinations and chemotherapy |
| Q30372931 | An overview of the characteristics of the novel avian influenza A H7N9 virus in humans. |
| Q93238882 | Antiviral agents against respiratory viruses |
| Q33226840 | Antiviral agents for influenza: a comparison of cost-effectiveness data |
| Q37136683 | Antiviral and antibiotic prescribing for influenza in primary care |
| Q39076394 | Antiviral therapy for respiratory viral infections in immunocompromised patients. |
| Q57094433 | Antiviral treatment for outpatient use during an influenza pandemic: a decision tree model of outcomes averted and cost-effectiveness |
| Q30352729 | Antivirals for influenza in healthy adults: systematic review. |
| Q34975814 | Antivirals for influenza: what is their role in the older patient? |
| Q40476247 | Appropriateness of antiviral prescribing for influenza in primary care: a retrospective analysis. |
| Q44078800 | Bedside rapid flu test and zanamivir prescription in healthy working adults: a cost-benefit analysis |
| Q28292279 | Binding of a natural anthocyanin inhibitor to influenza neuraminidase by mass spectrometry |
| Q40094706 | Biological Evaluation of Uridine Derivatives of 2-Deoxy Sugars as Potential Antiviral Compounds against Influenza A Virus |
| Q30362366 | Bird flu: lessons from SARS. |
| Q34594065 | Characterization of a broadly neutralizing monoclonal antibody that targets the fusion domain of group 2 influenza A virus hemagglutinin |
| Q35690541 | Clinical diagnosis of influenza in the ED. |
| Q40572821 | Clinical features of influenza A virus infection in older hospitalized persons |
| Q30229855 | Cost effectiveness of oseltamivir treatment for patients with influenza-like illness who are at increased risk for serious complications of influenza: illustration for the Netherlands |
| Q34171619 | Cost-utility of rapid polymerase chain reaction-based influenza testing for high-risk emergency department patients. |
| Q28349496 | Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities |
| Q78073768 | Deposition and disposition of [11C]zanamivir following administration as an intranasal spray. Evaluation with positron emission tomography |
| Q30391218 | Drugs in development for influenza |
| Q36020202 | Economic evaluations of neuraminidase inhibitors to control influenza |
| Q39424040 | Effect of zanamivir on duration and resolution of influenza symptoms |
| Q33780690 | Effectiveness and role of zanamivir in the treatment of influenza infection |
| Q30356962 | Effectiveness of neuraminidase inhibitors in preventing hospitalization during the H1N1 influenza pandemic in British Columbia, Canada. |
| Q34660518 | Efficacy and safety of clearing heat and detoxifying injection in the treatment of influenza: a randomized, double-blinded, placebo-controlled trial |
| Q40152886 | Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial |
| Q30204152 | Estimating the United States demand for influenza antivirals and the effect on severe influenza disease during a potential pandemic |
| Q41976366 | Evaluation and management of seasonal influenza in the emergency department |
| Q42200492 | Evaluation of intravenous peramivir for treatment of influenza in hospitalized patients |
| Q37366083 | Genotyping and detection of common avian and human origin-influenza viruses using a portable chemiluminescence imaging microarray |
| Q28201389 | Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention |
| Q33727502 | How to treat influenza and colds |
| Q74186218 | Impact of zanamivir treatment on productivity, health status and healthcare resource use in patients with influenza. Zanamivir Study Group |
| Q34083704 | In vitro and in vivo assay systems for study of influenza virus inhibitors |
| Q28349519 | In vivo influenza virus-inhibitory effects of the cyclopentane neuraminidase inhibitor RJW-270201 |
| Q22242958 | Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults |
| Q54079365 | Influenza |
| Q64916854 | Influenza Antiviral Prescribing Practices and the Influence of Rapid Testing Among Primary Care Providers in the US, 2009-2016. |
| Q40568364 | Influenza Diagnosis and Treatment : Impact of New Antivirals on Perceived Treatment Behaviours during Recent Influenza Outbreaks |
| Q30404293 | Influenza and HIV: lessons from the 2009 H1N1 influenza pandemic |
| Q37103929 | Influenza and respiratory syncytial virus in the elderly |
| Q35800321 | Influenza in the intensive care unit |
| Q37857854 | Influenza pharmacotherapy: present situation, strategies and hopes |
| Q30353587 | Influenza testing, diagnosis, and treatment in the emergency department in 2009-2010 and 2010-2011 |
| Q35063671 | Influenza vaccination and antiviral therapy: is there a role for concurrent administration in the institutionalised elderly? |
| Q30385118 | Influenza vaccines: from surveillance through production to protection. |
| Q30305461 | Influenza virus neuraminidase inhibitors |
| Q30411822 | Influenza virus resistance to neuraminidase inhibitors: implications for treatment |
| Q34219687 | Influenza. Cost of illness and considerations in the economic evaluation of new and emerging therapies |
| Q73235290 | Influenza: New Insights Into an Old Disease |
| Q26822988 | Inhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road ahead |
| Q35005030 | Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients |
| Q34480438 | Management of influenza in patients with asthma or chronic obstructive pulmonary disease |
| Q34742405 | Management of influenza symptoms in healthy adults |
| Q24540532 | Mutations in human parainfluenza virus type 3 hemagglutinin-neuraminidase causing increased receptor binding activity and resistance to the transition state sialic acid analog 4-GU-DANA (Zanamivir). |
| Q45386993 | Near-patient assays for diagnosis of influenza virus infection in adult patients |
| Q24559989 | Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells |
| Q24240097 | Neuraminidase inhibitors for preventing and treating influenza in healthy adults |
| Q24244898 | Neuraminidase inhibitors for preventing and treating influenza in healthy adults |
| Q24203905 | Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children |
| Q24644585 | Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis |
| Q35627874 | Neuraminidase inhibitors in patients with underlying airways disease |
| Q35045959 | Neuraminidase inhibitors in pediatric patients: potential place in influenza therapy |
| Q30332341 | New millennium antivirals against pandemic and epidemic influenza: the neuraminidase inhibitors. |
| Q30350342 | Novel strategies for prevention and treatment of influenza. |
| Q30353151 | Pandemics, avian influenza A (H5N1), and a strategy for pharmacists. |
| Q38375170 | Pharmacokinetics of MHAA4549A, an Anti-Influenza A Monoclonal Antibody, in Healthy Subjects Challenged with Influenza A Virus in a Phase IIa Randomized Trial |
| Q40083222 | Phase 2 Randomized Trial of the Safety and Efficacy of MHAA4549A, a Broadly Neutralizing Monoclonal Antibody, in a Human Influenza A Virus Challenge Model |
| Q37286996 | Preclinical pharmacokinetics of MHAA4549A, a human monoclonal antibody to influenza A virus, and the prediction of its efficacious clinical dose for the treatment of patients hospitalized with influenza A. |
| Q73202606 | Preparing for influenza epidemics and pandemics in the new millennium |
| Q34018854 | Prescription of anti-influenza drugs for healthy adults: a systematic review and meta-analysis. |
| Q64926265 | Principles of appropriate antibiotic use for treatment of uncomplicated acute bronchitis: background. |
| Q31992333 | Prophylactic and symptomatic treatment of influenza. Current and developing options |
| Q90422606 | Rapid Fire: Infectious Disease Emergencies in Patients with Cancer |
| Q30326042 | Recent progress in anti-influenza chemotherapy. |
| Q36937327 | Restoring invisible and abandoned trials: a call for people to publish the findings |
| Q38149216 | Review of the clinical effectiveness of the neuraminidase inhibitors against influenza B viruses. |
| Q36436765 | Role of sialic acid-containing molecules in paramyxovirus entry into the host cell: a minireview |
| Q40755954 | Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children |
| Q36565024 | Safety of neuraminidase inhibitors for influenza |
| Q46608987 | Scenarios on costs and savings of influenza treatment and prevention for Dutch healthy working adults |
| Q30357693 | Scientific lessons from the first influenza pandemic of the 20th century. |
| Q48585293 | Seasonal influenza in adults and children--diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America |
| Q37247935 | Simulation and prediction of the adaptive immune response to influenza A virus infection |
| Q35627901 | Spotlight on zanamivir in influenza |
| Q43023894 | Statins and influenza: can we move forward? |
| Q40153357 | Studies of the Interaction of Influenza Virus RNA Polymerase PAN with Endonuclease Inhibitors |
| Q28547982 | The Intranasal Application of Zanamivir and Carrageenan Is Synergistically Active against Influenza A Virus in the Murine Model |
| Q28344907 | The anti-influenza virus agent 4-GU-DANA (zanamivir) inhibits cell fusion mediated by human parainfluenza virus and influenza virus HA. |
| Q40662861 | The battle against influenza: The role of neuraminidase inhibitors in children |
| Q41835008 | The battle against influenza: The role of neuraminidase inhibitors in children. |
| Q57943670 | The burden of influenza B: a structured literature review |
| Q43727744 | The effect of zanamivir treatment on the early immune response to influenza vaccination |
| Q37292575 | The impact of influenza on working days lost: a review of the literature |
| Q30233313 | The threat and prospects for control of an influenza pandemic |
| Q30332377 | The treatment of influenza with antiviral drugs |
| Q34389114 | The use of antiviral drugs for influenza: Guidance for practitioners 2012/2013 |
| Q36171279 | The use of antiviral drugs for influenza: recommended guidelines for practitioners |
| Q43485506 | Treatment of aerosolized cowpox virus infection in mice with aerosolized cidofovir |
| Q30332727 | Treatment of epidemic and pandemic influenza with neuraminidase and M2 proton channel inhibitors |
| Q36411968 | Treatment of respiratory virus infections |
| Q30389265 | Update on antivirals and vaccines for seasonal and potential pandemic use. |
| Q34419670 | Vaccines for pneumonia and new antiviral therapies |
| Q30327921 | What is current opinion of antiviral therapy for the flu in 2001? |
| Q34229084 | Zanamivir and oseltamivir: two new options for the treatment and prevention of influenza |
| Q33978456 | Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies |
| Q33748023 | Zanamivir: a review of clinical safety |
| Q34481313 | Zanamivir: a review of clinical safety in individuals at high risk of developing influenza-related complications |
| Q33768776 | Zanamivir: a review of its use in influenza |
| Q40419399 | Zanamivir: an influenza virus neuraminidase inhibitor |
| Q34492611 | Zanamivir: an update of its use in influenza |
| Q28344586 | Zanamivir: from drug design to the clinic |
| Q73283416 | [New drugs for the treatment of influenza] |